Last reviewed · How we verify
Paroxysmal nocturnal hemoglobinuria
Approved treatments
- H5G1.1 · AstraZeneca
Eculizumab-aeeb binds to complement protein C5, inhibiting its cleavage and preventing terminal complement complex formation. - Ultomiris · AstraZeneca
Ultomiris blocks the action of Complement C5 to prevent inflammation and damage to red blood cells. - Fabhalta · Novartis
Iptacopan binds to Factor B, regulating C3 cleavage and downstream effects in the alternative complement pathway, controlling IVH and EVH in PNH and inhibiting local activation in IgAN and C3G. - ULTOMIRIS · ALEXION PHARM
- Ultomiris · Alexion Pharmaceuticals, Inc.
- Soliris · Apellis Pharmaceuticals, Inc.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Paroxysmal nocturnal hemoglobinuria patent landscape — cliff calendar, originator estates, attackable patents
- Paroxysmal nocturnal hemoglobinuria treatment landscape brief
- Paroxysmal nocturnal hemoglobinuria treatment updates RSS
Frequently asked questions about Paroxysmal nocturnal hemoglobinuria
What drugs treat Paroxysmal nocturnal hemoglobinuria?
Tracked treatments include H5G1.1, Ultomiris, Fabhalta, ULTOMIRIS, Soliris.
What is the treatment for Paroxysmal nocturnal hemoglobinuria?
Standard treatment for Paroxysmal nocturnal hemoglobinuria includes H5G1.1, Ultomiris, Fabhalta, ULTOMIRIS, Soliris. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Paroxysmal nocturnal hemoglobinuria patent cliff · Paroxysmal nocturnal hemoglobinuria CI report
- Treatment: H5G1.1 · AstraZeneca
- Treatment: Ultomiris · AstraZeneca
- Treatment: Fabhalta · Novartis
- Treatment: ULTOMIRIS · ALEXION PHARM
- Treatment: Ultomiris · Alexion Pharmaceuticals, Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing